Stock-market volatility in India is staying elevated unlike in the rest of Asia, signaling deeper investor unease about the nation’s energy exposure, high valuations and renewed focus on corporate governance troubles. India’s volatility gauge remains near its March 9 peak, which was the highest since June 2024. Similar measures for Japan and South Korea, countries that rely heavily on fuel shipped...
Stock-market volatility in India is staying elevated unlike in the rest of Asia, signaling deeper investor unease about the nation’s energy exposure, high valuations and renewed focus on corporate governance troubles. India’s volatility gauge remains near its March 9 peak, which was the highest since June 2024. Similar measures for Japan and South Korea, countries that rely heavily on fuel shipped through the Strait of Hormuz, have dropped from their respective Iran war–driven highs. The Cboe Volatility Index has also eased. The divergence suggests India’s risk premium is turning stickier with the energy shock hitting the economy. Even before the conflict, India faced high valuations, the risk of AI disruption without notable chipmakers, and currency weakness. The selloff has pushed its stocks benchmark near levels last seen during the market turmoil after the US tariff rollout a year ago, just as governance concerns erupted at the nation’s biggest private-sector bank. “Elevated oil prices, rupee at record lows, sustained foreign outflows, and high valuations together form a challenging macro backdrop, for equities to deliver immediately,” said Gary Dugan , chief executive officer at the Global CIO Office. “Even if the geopolitical temperature cools, there is still meaningful downside if domestic concerns linger.” The NSE Nifty 50 Index has lost 11% this year, compared with a gain of about 5% gain in the MSCI Asia-Pacific Index. Among equity gauges in countries exposed to the Iran energy shock, Korea’s Kospi is up 37%, while Japan’s Nikkei 225 is up 6%. “India’s volatility reflects more than geopolitics,” said Song Zhe , an investment specialist for emerging-market equities at BNP Paribas Asset Management. “India needs to win back attention on its own merits — better earnings breadth, a steadier rupee, lower oil anxiety and valuations that are compelling rather than merely less expensive.” The energy exposure is the most immediate problem . India imports roughly 90%...
The S&P 500 on Thursday snapped a 214-session run over its 200-day average — but an examination of the data finds dipping below isn’t necessarily so terrible.
The S&P 500 on Thursday snapped a 214-session run over its 200-day average — but an examination of the data finds dipping below isn’t necessarily so terrible.
格隆汇3月20日｜随着中东紧张局势主导市场，欧元信用债的违约保险成本大幅上升。能源价格与战前水平相比仍然高企，这导致投资者开始计入高通胀和主要央行可能加息的风险。标普全球市场财智的数据显示，iTraxx Europe Crossover欧元高收益信用违约掉期指数上升24个基点，至335个基点，为10个半月来的最高水平。
格隆汇3月20日｜随着中东紧张局势主导市场，欧元信用债的违约保险成本大幅上升。能源价格与战前水平相比仍然高企，这导致投资者开始计入高通胀和主要央行可能加息的风险。标普全球市场财智的数据显示，iTraxx Europe Crossover欧元高收益信用违约掉期指数上升24个基点，至335个基点，为10个半月来的最高水平。
Super Micro Computer placed two employees on leave and fired a contractor after charges of diverting U.S.-assembled servers to China, violating export control laws.
Super Micro Computer placed two employees on leave and fired a contractor after charges of diverting U.S.-assembled servers to China, violating export control laws.
Ride-sharing company Uber Technologies (UBER 1.72%) is throwing its hat in the robotaxi ring. Yesterday, Uber inked a $1.25 billion deal with EV maker Rivian Automotive (RIVN +3.70%) to aggressively expand its robotaxi capabilities. The move comes as competition intensifies in the robotaxi space, with Tesla -- the largest electric vehicle (EV) stock on the planet -- planning to invest heavily in t...
Ride-sharing company Uber Technologies (UBER 1.72%) is throwing its hat in the robotaxi ring. Yesterday, Uber inked a $1.25 billion deal with EV maker Rivian Automotive (RIVN +3.70%) to aggressively expand its robotaxi capabilities. The move comes as competition intensifies in the robotaxi space, with Tesla -- the largest electric vehicle (EV) stock on the planet -- planning to invest heavily in the robotaxi market. That market opportunity, at least according to some experts, could be worth $5 trillion to $10 trillion globally over the long term, making it a key long-term battleground for both automakers and mobility platforms. Here are the top four things to know about the latest deal. Expand NASDAQ : RIVN Rivian Automotive Today's Change ( 3.70 %) $ 0.57 Current Price $ 16.11 Key Data Points Market Cap $20B Day's Range $ 15.55 - $ 17.11 52wk Range $ 10.36 - $ 22.69 Volume 432 Avg Vol 31M Gross Margin -276.59 % 1. Rivian will supply Uber with 50,000 vehicles over the next five years Let's first discuss the details of the partnership between Uber and Rivian. It's important to know that Uber is no longer developing its own self-driving software, having ditched its internal efforts back in 2020. Uber also doesn't manufacture any of its own vehicles. So if Uber wants to target the nascent robotaxi market, it will need to partner with companies that not only manufacture vehicles but are also developing their own self-driving features. Here are the exact details of the deal from today's press release: Uber will invest up to $1.25 billion in Rivian through 2031, subject to the achievement of autonomous performance milestones. Uber or its fleet partners will purchase 10,000 fully autonomous R2 robotaxis with the option to purchase up to 40,000 more in 2030. Initial commercial deployments for the Uber-Rivian robotaxi service are planned for San Francisco and Miami in 2028, scaling to 25 cities through 2031. 2. Uber will help Rivian achieve fully autonomous vehicles I recent...
However there is a debate over whether that help should be universal, distributed to all households, or targeted at vulnerable and low-income houses. A targeted approach would allow more money to be given to households in need and would cost less, at a time when government spending is stretched.
However there is a debate over whether that help should be universal, distributed to all households, or targeted at vulnerable and low-income houses. A targeted approach would allow more money to be given to households in need and would cost less, at a time when government spending is stretched.
Also in 2016, President Barack Obama became the first serving US president to visit Hiroshima, saying his visit was "a testament to how even the most painful divides can be bridged - how our two nations, former adversaries, cannot just become partners, but become the best of friends and the strongest of allies".
Also in 2016, President Barack Obama became the first serving US president to visit Hiroshima, saying his visit was "a testament to how even the most painful divides can be bridged - how our two nations, former adversaries, cannot just become partners, but become the best of friends and the strongest of allies".
Key Points Abivax is viewed as a buyout candidate thanks to its promising lead drug candidate, obefazimod. Abivax is testing obefazimod for multiple conditions. Nektar Therapeutics shares are up by 77% so far in 2026. 10 stocks we like better than Abivax Société Anonyme › Abivax (NASDAQ: ABVX) and Nektar Therapeutics (NASDAQ: NKTR) aren't well-known companies, and they don't have track records of ...
Key Points Abivax is viewed as a buyout candidate thanks to its promising lead drug candidate, obefazimod. Abivax is testing obefazimod for multiple conditions. Nektar Therapeutics shares are up by 77% so far in 2026. 10 stocks we like better than Abivax Société Anonyme › Abivax (NASDAQ: ABVX) and Nektar Therapeutics (NASDAQ: NKTR) aren't well-known companies, and they don't have track records of profitability yet. That's natural, as both are clinical-stage biotechs -- they don't have any approved drugs on the market yet. However, both are developing novel therapies with blockbuster potential, and both could be worthwhile stocks to own. Abivax is down by around 10% this year, while Nektar is up by about 77%. Here are three reasons to consider buying each stock. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Abivax 1. A potential blockbuster in obefazimod French biotech Abivax is developing therapies for chronic inflammatory diseases. Its lead candidate is obefazimod, which is being tested to treat ulcerative colitis, Crohn's disease, and other conditions. The oral therapy is in a phase 3 trial to treat moderately to severely active ulcerative colitis. The company expects to publish top-line data from that trial in the second quarter; if the drug continues to perform as hoped, Abivax would be on its way to getting its first therapy approved by regulators, and one that could eventually be useful in multiple indications. The drug is also in a phase 2b trial for Crohn's disease, with top-line results expected in the fourth quarter. Abivax could easily become a blockbuster. According to one study, the ulcerative colitis market alone will be worth $8.7 billion in 2026 but is forecast to grow to $14.3 billion by 2035. 2. Possible buyout bids Though its shares are down so far in 2026, they're up by more ...